PTK2 and nasopharyngeal carcinoma: Masitinib, as a novel and effective tyrosine kinase inhibitor, can block the FAK cell pathway by inhibiting FAK phosphorylation and thus has the potential to be a targeted therapeutic agent for NPC [56].